RecruitingPhase 2NCT06534437
MEN1703 (SEL24) to Treat Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma (JASPIS-01)
Studying Aggressive B-cell non-Hodgkin lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ryvu Therapeutics SA
- Intervention
- MEN1703(drug)
- Enrollment
- 178 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (30)
- Centre Hospitalier Le Mans, Le Mans, France
- CHU de Lille - Hôpital Claude Huriez, Lille, France
- CHU de Limoges - CHU Dupuytren, Limoges, France
- Hospices Civils De Lyon - Hôpital Lyon Sud, Lyon, France
- CHU Montpellier - Hôpital Saint Eloi, Montpellier, France
- APHP - Hôpital Pitié-Salpêtrière, Paris, France
- CHU de Bordeaux - Hôpital Haut-Lévêque, Pessac, France
- Wojewódzki Szpital Specjalistyczny w Białej Podlaskiej, Biała Podlaska, Poland
- IN-VIVO Bydgoszcz Sp. z o.o., Bydgoszcz, Poland
- Klinika Hematologii I Transplantologii Uck, Gdansk, Poland
- Szpitale Pomorskie Sp. z o.o., Gdynia, Poland
- Narodowy Instytut Onkologii im. Marii Skłodowskiej Curie, Państwowy Instytut Badawczy, Gliwice, Poland
- Pratia Hematologia Sp. z o.o., Katowice, Poland
- Pratia MCM Kraków, Krakow, Poland
- SP ZOZ Szpital Uniwersytecki w Krakowie, Krakow, Poland
- +15 more locations on ClinicalTrials.gov
Collaborators
Menarini Group
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06534437 on ClinicalTrials.govOther trials for Aggressive B-cell non-Hodgkin lymphoma
Additional recruiting or active studies for the same condition.
- ENROLLING BY INVITATIONNCT07474051Long-Term Follow-Up of AvenCell Sponsored CAR-T Cell Clinical TrialsAvenCell Therapeutics, Inc.
- RECRUITINGEARLY PHASE1NCT07344818An Open and Dose-escalation Early Clinical Study of CD19 and CD20 CAR-T Cell Therapy for Relapsed or Refractory Aggressive B-cell LymphomaPeking University People's Hospital
- RECRUITINGPHASE2NCT07097363Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaUniversity of Washington
- RECRUITINGPHASE2NCT06649812Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell LymphomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2, PHASE3NCT07168980Chemotherapy With Rituximab for Aggressive B-NHL in Children and AdolescentsChildren's Cancer Group, China
- RECRUITINGPHASE2NCT06996132Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell LymphomaInstitute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE1, PHASE2NCT06536049Epcoritamab Plus Ibrutinib for the Treatment of Relapsed or Refractory Aggressive B-Cell Non-Hodgkin LymphomaYazeed Sawalha
- RECRUITINGPHASE2NCT06834373Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell TherapyMayo Clinic